Update on other OPBC research projects
OPBC-04/EUBREAST-06-OMA
Principal Investigator: Giacomo Montagna (Memorial Sloan Kettering Cancer Center, New York, USA)
In this first collaboration between OPBC and EUBREAST, a total of 1144 limited axillary surgery procedures – 478 targeted axillary dissections and 666 sentinel node procedures – in cN+ converting to ycN0 were included at 25 sites in 11 countries. After successful oral presentation at the San Antonio Beast Cancer Symposium on 09 December 22, see picture below, the manuscript is currently being written.
Now we plan to use the same multicenter design to compare axillary dissection with axillary radiation for residual isolated tumor cells in the nodes after neoadjuvant systemic therapy. The call for participation with a study synopsis will be sent by newsletter in January. This will be another fast and successful project.
OPBC-03/TAXIS
Principial Investigator: Walter Weber (University Hospital Basel, Switzerland)
Budget: 7.5 Mio CHF (SCL/SCR, multiple foundations)
Two TAXIS sub-studies were accepted for oral presentation at the annual meeting of the Society of Surgical Oncology on 25 March 2023 in Boston.
We currently enrolled 639 of 1500 patients in Switzerland, Hungary, Austria, Germany and Lithuania. Further sites are currently being evaluated for TAXIS trial participation in Argentina, Croatia, Greece, Italy, Brazil, Canada and Qatar.
If you are interested in trial participation, please send an email to walter.weber@usb.ch to initiate the evaluation of your site.
> Publication of first pre-specified subproject
> Trial registration
OPBC-02/PREPEC
Principial Investigator: Walter Weber (University Hospital Basel, Switzerland)
Budget: 2 Mio CHF (SNF IICT/SCL/SCR)
We currently enrolled 369 of 372 patients in Switzerland, Germany, Sweden, Hungary, Austria, USA, Italy, Israel and Argentina. We estimate that accrual will be completed within a few weeks. Therefore, no additional site participation can be evaluated.
> Trial registration
> Published protocol
|
